Eurazeo announces the acquisition of the remaining shares in Kurma Partners, a French asset management company specialising in biotechnology and medical innovation. This transaction follows Eurazeo’s majority stake acquisition (70.6%) in 2021, in line with the agreements signed at the time.
With nearly €600 million in assets under management, Kurma Partners has established itself since 2009 as a key player in the European healthcare sector, supporting the most promising companies in the field. The recent first closing of Kurma Biofund IV (€140 million – SFDR article 8) illustrates its leading role in financing innovative therapeutic solutions.
Recent trade exits (Amolyt Pharma, Emergence Therapeutics, Still Technologies) highlight its ability to create value and support the emergence of European leaders.
Since 2021, Eurazeo, a long-standing investor in Kurma, has already committed nearly €100 million to its funds and has provided operational support as well as access to its international platform. The Group will continue to actively support Kurma Partners’ growth.
This increased stake forms part of Eurazeo’s broader commitment to the healthcare sector, through both generalist and specialist funds. By the end of 2024, the Group’s assets under management dedicated to healthcare investments total €3 billion.
Christophe Bavière and William Kadouch-Chassaing, Co-CEOs of Eurazeo, declared:
“Healthcare innovation is a strategic sector for Eurazeo. This acquisition strengthens our platform in early-stage investment, while preserving Kurma Partners’ entrepreneurial DNA and operational independence.“
Rémi Droller, Managing Partner at Kurma Partners, added:
“The strength of the Eurazeo–Kurma platform reinforces our European ambition and amplifies our impact in healthcare. Together, we are building a leading player in medical innovation across Europe.“
